Jubilant Pharmova receives USFDA approval for Line 3 at Spokane facility
Jubilant Pharmova · Pharmaceuticals & Biotechnology
Key highlights
- USFDA approved commercial batch manufacturing on Line 3 of Jubilant HollisterStier LLC, Spokane, USA.
- Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., under Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of Jubilant Pharmova Limited.
- Approval received on August 21, 2026 (PST) / August 22, 2026 (IST).
Why it's rated notable: The filing reports a USFDA approval for commercial batch manufacturing on a new line at a subsidiary's facility but states no amount, so the level stays at the medium default.
Original filing
USFDA Approval For Line 3, Contract Manufacturing Facility, Spokane, U.S.A
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Jubilant Pharmova
- Fundraise / allotmentNotableJubilant Pharmova Allots ₹800 Crore Non-Convertible Debentures on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova allots ₹800 crore NCDs via private placement on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova approves issuance of up to ₹800 crore NCDs on private placement
- Order winNotable· Adverse for the businessJubilant Pharmova reports USFDA Warning Letter for Montreal contract manufacturing site
Other order win filings this fortnight
- HLE Glascoat subsidiary Kinam Engineering secures $42-48M international order
- SpectraA Technology Solutions receives ₹21 crore domestic order for brewery project
- Ashoka Buildcon receives LoA for NHAI expressway project worth ₹865.90 crore
- L&T bags significant order from Noida Metro for Aqua Line Extension
- South West Pinnacle Exploration H1 FY27 revenue up 16% to Rs. 1194 Mn, PAT up 23%
- SEAMEC Limited awarded USD 26.14 million subsea installation contract by L&T
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.